Avinger, Inc. (AVGR)
Stock Price:
$0.266 USD
-0.014 (-5.00%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $0.270 +0.004 (1.47%) Oct 27, 7:53 PM
Key Info
| Market Cap |
22.59M |
| Revenue (ttm) |
8.70M |
| Net Income (ttm) |
-19.60M |
| Shares Out |
84.92M |
| EPS (ttm) |
-1.55 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$0.266 |
| Previous Close |
$0.280 |
| Change ($) |
-0.014 |
| Change (%) |
-5.00% |
| Day's Open |
0.280 |
| Day's Range |
0.262 - 0.282 |
| Day's Volume |
3,119,163 |
| 52-Week Range |
0.241 - 1.630 |
More Stats
| Market Cap |
22.59M |
| Enterprise Value |
18.15M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
84.92M |
| Float |
84.58M |
| EPS (basic) |
-1.78 |
| EPS (diluted) |
-1.55 |
| FCF / Share |
-0.59 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
539,509 |
| Short Ratio |
0.14 |
| Short % of Float |
0.64% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.60 |
| PB Ratio |
3.35 |
| Revenue |
8.70M |
| Operating Income |
-18.70M |
| Net Income |
-19.60M |
| Free Cash Flow |
-16.04M |
| Net Cash |
4.44M |
| Net Cash / Share |
0.05 |
| Gross Margin |
32.96% |
| Operating Margin |
-214.93% |
| Profit Margin |
-268.10% |
| FCF Margin |
-184.43% |
| ROA |
-40.50% |
| ROE |
-224.34% |
| ROIC |
-223.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
1 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Low
1.00
Current: $0.266
High
1.00
Target: 1.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 9.13 | 7.92 | 9.93 | 19.21 | 10.71 | 11.21 | 12.96 | 8.56 |
| Revenue Growth | 15.36% | -20.32% | -48.3% | 79.35% | -4.46% | -13.51% | 51.45% | - |
| Gross Profit | 2.87 | 1.38 | -3.07 | 4.77 | 4.24 | 4.70 | 4.76 | 4.41 |
| Operating Income | -19.36 | -23.03 | -42.55 | -50.72 | -40.69 | -25.03 | -36.97 | -33.86 |
| Net Income | -19.45 | -27.56 | -48.73 | -56.13 | -47.34 | -31.96 | -39.90 | -33.86 |
| Shares Outstanding | 7.24 | 1.07 | 0.07 | 0.04 | 0.03 | - | - | - |
| Earnings Per Share | -3.18 | -33.42 | -749.72 | -1,355.70 | -1,751.00 | -53,273.30 | -68,208.00 | -64,812.00 |
| Operating Cash Flow | -17.26 | -18.47 | -34.48 | -53.07 | -40.88 | -21.80 | -40.66 | -35.23 |
| Capital Expenditures | -0.07 | - | -0.04 | -0.97 | -0.58 | -0.12 | -0.50 | -0.29 |
| Free Cash Flow | -17.33 | -18.47 | -34.52 | -54.04 | -41.46 | -21.92 | -41.15 | -35.52 |
| Cash & Equivalents | 10.94 | 16.41 | 5.39 | 36.10 | 43.06 | 12.32 | 12.22 | 20.62 |
| Total Debt | 8.97 | 7.49 | 44.74 | 41.29 | 29.57 | 28.71 | 33.78 | - |
| Net Cash / Debt | 1.98 | 8.92 | -39.36 | -5.19 | 13.49 | -16.39 | -21.56 | 20.62 |
| Assets | 23.83 | 23.70 | 15.09 | 53.56 | 54.10 | 24.44 | 25.01 | 30.32 |
| Liabilities | 16.93 | 14.24 | 50.78 | 49.32 | 38.52 | 36.05 | 38.14 | 4.31 |
| Book Value | 6.90 | 9.46 | -35.69 | 4.24 | 15.59 | -144 | -113 | -73.64 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Avinger, Inc. |
| Country |
United States |
| Employees |
74 |
| CEO |
Jeffrey M. Soinski |
Stock Information
| Ticker Symbol |
AVGR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: AVGR |
| IPO Date |
January 30, 2015 |
Description
Avinger, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.